High Flow Nasal Cannula
OtherEvaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
NCT Number: NCT02791711
The aim of this study is to evaluate the use of nasal broadband glasses HFNC (High Flow Nasal Cannula) in the initial management of severe bronchiolitis in infants admitted in ICU.
Nasal HFNC can deliver warmed humidified gas through a nasal interface, greatly improving the safety and efficacy of administering O2. This device generates a continuous positive pressure in the airways, to reduce the work of breathing. The sealing absence of the HFNC at the nasal interface improves patient comfort and avoiding nasal trauma.
Looking for future studies?
Notify MeUp to 1 year
All sexes
Interventional
Not applicable
Hôpital Arnaud de Villeneuve - CHU de Montpellier, Montpellier, France
Bronchiolitis in infants is a common and potentially serious disease. It corresponds to an acute pulmonary disease and dyspnea usually viral (70 to 80% of Respiratory syncytial virus (RSV) in infants less than 1 year). It particularly affects infants under 2 years.
The 2001 consensus conference and bronchiolitis 2006 on the management clarified the criteria for hospitalization and simplified therapeutic attitudes. These conferences have highlighted the importance of humidification, the nasopharyngeal desobstruction for less severe forms of oxygen therapy and for others. Recent literature has also shown that the use of noninvasive ventilation type Continuous Positive Airway Pressure (CPAP) nasal or broadband nasal glasses (HFNC: High Flow Nasal canula) in severe forms possible to reduce the work of breathing of children with severe bronchiolitis and their use in studies "before / after" was accompanied by a significant decrease in the use of invasive ventilation.
The HFNC and nasal CPAP can deliver warmed humidified gas through a nasal interface, greatly improving the safety and efficacy of administering O2. These devices generate a continuous positive pressure in the airways, for decreasing the work of breathing. The sealing absence of the HFNC at the nasal interface improves patient comfort and avoiding nasal trauma, sometimes encountered with nasal CPAP interfaces.
The HFNC is a simple, effective and safe, commonly used in severe bronchiolitis admitted in ICU (Intensive Care Unit). However instead of this technique is not yet well defined.
The investigators assume that the use of HFNC in severe bronchiolitis in first line allows sufficient respiratory improvement to avoid recourse to other technical assistance ventilatory more binding.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
EN> 50 quiet,
Exclusion criteria
Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
Time frame: after one hour of treatment
the number of children who once set HFNC at baseline Hour 0 will not need another breathing assistance technique After 1 hour H1 of treatment
Time frame: Comparison between baseline Hour 0 and after 1 hour of treatment
Number of children who will not need another technique while respiratory assistance throughout the ICU stay
Time frame: At baseline hour 0
Correlation of demographic data Hour 0 to failure of HFNC
Time frame: At baseline hour 0
Correlation of clinical data Hour 0 to failure of HFNC
Time frame: comparison to Hour 0, Hour 1, Hour 12
Neonatal pain and discomfort scale " Échelle Douleur Inconfort Nouveau-Né" (EDIN)) Scores comparison to Hour 0, Hour 1, Hour 12
This scale evaluates the prolonged pain and discomfort of the child, an hetero assesor measures by 5 items about face, body, sleep, comfort and relationship. Each item scores from 0 to 5. 0 means no pain or discomfort symptoms and 5 means the maximum symptoms.
Global score will be from 0 to 15.
Time frame: From baseline hour 0 to the end of hospitalization
Frequency and types of adverse events throughout the ICU hospitalization period
Time frame: Comparison between baseline Hour 0 and after 1 hour of treatment
comparaison of clinical data between baseline and 1 Hour of HFNC application.
Fondation Lenval
Other
Using Nasal Broadband Glasses HFNC (High Flow Nasal Cannula) in the Initial Management of Severe Bronchiolitis in Infants Admitted in ICU: Bicentric Observational Study on the 2013-2014 Epidemic
Acronym: HFNC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06932341
Bronchial Diseases, Bronchiolitis
St. Petersburg, Florida, United States
View Trial DetailsNCT06016244
Bronchial Diseases, Bronchial Hyperreactivity
Haarlem, North Holland, Netherlands
View Trial DetailsNCT02824744
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial DetailsNCT03298217
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial Details